Limitless Wellness

CJC1295 - NO DAC

1000.00 AED — In stock

CJC1295 - NO DAC

CJC-1295 (No DAC) is a synthetic growth hormone–releasing hormone (GHRH) analogue designed for research into pulsatile growth hormone (GH) secretion. Unlike the DAC-modified version, No DAC has a shorter half-life, making it ideal for studies focused on natural GH pulse dynamics rather than prolonged elevation. This peptide is widely investigated in endocrine, metabolic, recovery, and body composition research, particularly where controlled GH release is preferred. Key Features 💉 Research-grade peptide formulation⏱️ Short-acting (No DAC) for physiologic GH pulsatility🧬 Mimics endogenous GHRH signalling🧪 High-purity, laboratory-tested compound📄 Supplied for laboratory research use only Key Research Benefits 📈 Stimulates Endogenous Growth Hormone Release• Activates pituitary GH secretion through GHRH receptor binding ⚙️ Supports Natural GH Pulses• Short half-life allows investigation of physiologic GH rhythm 💪 Recovery & Tissue Repair Research• Relevant to studies on muscle recovery, connective tissue, and regeneration pathways 🔥 Metabolic & Fat Utilisation Research• GH signalling plays a role in lipolysis and metabolic efficiency 🧠 Sleep & Circadian Rhythm Studies• GH release is closely linked to sleep-related endocrine patterns Mechanism Overview CJC-1295 (No DAC) binds to GHRH receptors in the pituitary, stimulating: Growth hormone secretion IGF-1 signalling (indirectly) Protein synthesis and tissue repair pathways The No DAC structure ensures rapid clearance, supporting short-duration GH signalling rather than sustained elevation. Human-Relevant Research Applications 🔬 Endocrine and GH pulse modelling🔬 Recovery and tissue repair research🔬 Metabolic and fat-oxidation pathways🔬 Sleep-related hormone regulation🔬 Performance and longevity signalling studies

More All Products

What is CJC1295 - NO DAC?

Mod GRF 1-29 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is made of the first 29 amino acids of human GHRH, the shortest fragment that keeps full activity. Four amino acids are swapped, at positions 2, 8, 15 and 27, to make it more stable than the natural sequence.

Natural GHRH is broken down in the blood within minutes. The substitutions are designed to slow this down, while keeping a relatively short action compared with CJC-1295 with DAC. It acts on GHRH receptors in the pituitary gland, which is thought to prompt the release of the body's own growth hormone.

Also known as: Mod GRF 1-29, Modified GRF (1-29), Tetrasubstituted GRF(1-29), CJC-1295 no DAC

What are peptides?

What the research covers

The individual changes used in Mod GRF 1-29 have been studied in laboratory, animal and small human studies. Research showed that natural GHRH is rapidly broken down by a plasma enzyme. A small study in healthy men found that replacing the second amino acid with D-alanine increased the half-life of GHRH(1-29). The same core sequence forms the basis of CJC-1295 with DAC. There are few published clinical studies of Mod GRF 1-29 itself, so evidence on its long-term effects and safety is limited. Mod GRF 1-29 is not approved as a medicine by the US FDA.

References

  1. Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. The Journal of Clinical Endocrinology and Metabolism. 1994.
  2. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. The Journal of Clinical Investigation. 1986.
  3. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005.

Formats available

Vial (injectable)

Lyophilised powder in a sterile vial, reconstituted before subcutaneous injection as directed by your pharmacy.

Storage and handling

Storage: Keep unopened lyophilised vials cool and dry, away from light. After reconstitution, refrigerate at 2-8C, protect from light and do not freeze. Follow the storage instructions on your pharmacy label.

Peptide Calculator

Specification

PropertyValue
SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Molecular formulaC152H252N44O42
Molecular weightapprox. 3368 g/mol
Peptide length29 amino acids
FormatsVial (injectable)

Frequently asked questions

What does the research on Mod GRF 1-29 show?

Research has focused on why the amino acid changes make GHRH(1-29) more stable. There are few clinical studies of Mod GRF 1-29 itself, so the evidence base is limited.

How is it different from sermorelin?

Sermorelin is the unmodified GHRH(1-29) sequence. Mod GRF 1-29 has four amino acid substitutions designed to make it last longer in the blood. Neither contains the DAC linker found in CJC-1295 with DAC.

Are there side effects with CJC-1295 without DAC (Mod GRF 1-29)?

Side effects can occur. Your GP will review your health, medication and, where relevant, blood results before prescribing, and you should report anything unexpected.

Which formats are available and how should I store them?

CJC-1295 without DAC (Mod GRF 1-29) is available as a vial (injectable). Keep unopened lyophilised vials cool and dry, away from light. After reconstitution, refrigerate at 2-8C, protect from light and do not freeze. Follow the storage instructions on your pharmacy label.

How much CJC-1295 without DAC (Mod GRF 1-29) should I take?

Your dose is set by our licensed GP following a consultation, and printed on your pharmacy label.

Related products

LIMITLESS